{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:48:24Z","timestamp":1784753304097,"version":"3.55.0"},"reference-count":16,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"3","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":316,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Several psychoactive medications are known to cause QTc prolongation. Patient factors also increase the risk for QTc prolongation, including bradycardia, female sex, older age, metabolic abnormalities, and polypharmacy. Donepezil, a cholinesterase inhibitor, prolongs the QTc interval through a multimodal mechanism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patient History<\/jats:title>\n                  <jats:p>A 26-year-old African American female was admitted to the inpatient psychiatric hospital following a suicide attempt that was not an overdose. Past medical history was significant for major depression, traumatic brain injury, seizures, hemiplegia, gastroesophageal reflux disease, and tachycardia. Two baseline electrocardiograms (EKGs) were obtained showing normal QTc intervals. After several weeks, donepezil (5 mg by mouth once daily) was initiated for cognitive rehabilitation and titrated over 3 weeks to a dose of 20 mg. An EKG performed after the last dose change showed a prolonged QTc of 463 ms. Another follow-up EKG performed 9 days later showed further prolongation to 528 ms. Laboratory values were within normal limits during her hospital stay. Donepezil was discontinued completely, leading to normalization of the QTc interval.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>QTc prolongation and torsades de pointes have been identified in postmarketing case reports of donepezil. Instances of QTc prolongation have predominantly been documented in the geriatric population, primarily in those with additional risk factors. Additionally, current literature does not support the use of donepezil for neurocognitive rehabilitation in daily doses exceeding 10 mg. A temporal and causal relationship was observed between the initiation and titration of donepezil and development of QTc prolongation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2019.05.128","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T13:43:39Z","timestamp":1557495819000},"page":"128-132","source":"Crossref","is-referenced-by-count":15,"title":["Donepezil-induced QTc prolongation: A case report"],"prefix":"10.9740","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6281-7038","authenticated-orcid":false,"given":"Samantha M.","family":"Vogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2852-6632","authenticated-orcid":false,"given":"Lisa M.","family":"Mican","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-4919","authenticated-orcid":false,"given":"Tawny L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"issue":"8","key":"2020060307353272600_i2168-9709-9-3-128-b01","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"2020060307353272600_i2168-9709-9-3-128-b02","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/CCM.0b013e318232db4a","article-title":"High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality","volume":"40","author":"Pickham","year":"2012","journal-title":"Crit Care Med"},{"issue":"5","key":"2020060307353272600_i2168-9709-9-3-128-b03","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4088\/PCC.v05n0504","article-title":"New generation antipsychotic drugs and QTc interval prolongation","volume":"5","author":"Vieweg","year":"2003","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"2","key":"2020060307353272600_i2168-9709-9-3-128-b04","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2174\/1573403x12666160301120217","article-title":"Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias","volume":"12","author":"Cubeddu","year":"2016","journal-title":"Curr Cardiol Rev"},{"key":"2020060307353272600_i2168-9709-9-3-128-b05","article-title":"DONEPEZIL HYDROCHLORIDE (donepezil hydrochloride) tablet, film coated. 1996 [rev. 2016 Feb; cited 2018 Jun 19]","author":"Jublient Cadista Pharmaceuticals Inc","journal-title":"DailyMed [Internet]"},{"issue":"9","key":"2020060307353272600_i2168-9709-9-3-128-b06","doi-asserted-by":"publisher","first-page":"1386.e1","DOI":"10.1016\/j.ajem.2017.06.044","article-title":"Cholinergic symptoms and QTc prolongation following donepezil overdose","volume":"35","author":"Pourmand","year":"2017","journal-title":"Am J Emerg Med"},{"key":"2020060307353272600_i2168-9709-9-3-128-b07","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-211900","article-title":"A case of donepezil-related torsades de pointes","author":"Kitt","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2020060307353272600_i2168-9709-9-3-128-b08","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1248\/yakushi.132.237","article-title":"Shortening of donepezil-induced QTc prolongation with a change in the interacting drug, after electrocardiograph monitoring by community pharmacists: a case report","volume":"132","author":"Shinozaki","year":"2012","journal-title":"Yakugaku Zasshi"},{"issue":"3","key":"2020060307353272600_i2168-9709-9-3-128-b09","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jjcc.2009.03.011","article-title":"Torsades de pointes with QT prolongation related to donepezil use","volume":"54","author":"Takaya","year":"2009","journal-title":"J Cardiol"},{"issue":"14","key":"2020060307353272600_i2168-9709-9-3-128-b10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2169\/internalmedicine.48.2181","article-title":"Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and torsade de pointes","volume":"48","author":"Tanaka","year":"2009","journal-title":"Intern Med"},{"issue":"3","key":"2020060307353272600_i2168-9709-9-3-128-b11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/hup.2398","article-title":"Cardiovascular pharmacodynamics of donepezil hydrochloride on the PR and QT intervals in patients with dementia","volume":"29","author":"Igeta","year":"2014","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"2020060307353272600_i2168-9709-9-3-128-b12","article-title":"CredibleMeds: risk categories for drugs that prolong QT & induce torsades de pointes (TdP)","author":"Woosley","journal-title":"[Internet]"},{"issue":"41","key":"2020060307353272600_i2168-9709-9-3-128-b13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3238\/arztebl.2011.0687","article-title":"QTc prolongation by psychotropic drugs and the risk of torsade de pointes","volume":"108","author":"Wenzel-Seifert","year":"2011","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"2020060307353272600_i2168-9709-9-3-128-b14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/2045125313510194","article-title":"Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports","volume":"4","author":"Hasnain","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"issue":"3","key":"2020060307353272600_i2168-9709-9-3-128-b15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/01.HTR.0000319935.99837.96","article-title":"The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review","volume":"23","author":"Ballesteros","year":"2008","journal-title":"J Head Trauma Rehabil"},{"issue":"2","key":"2020060307353272600_i2168-9709-9-3-128-b16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/3\/128\/2429013\/mhc_2019_05_128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/3\/128\/2429013\/mhc_2019_05_128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:22:57Z","timestamp":1731687777000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/9\/3\/article-p128.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2019.05.128","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}